Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lagis Enterprise CoROCO:6730 91 EBITDA Margin % is 28.57% as of Dec. 2025, which is 5% above its 10-year median of 27.19. GuruFocus rates ROCO:6730 with a GF Score™ of 91/100 and a GF Value™ of NT$43.10 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Lagis Enterprise Co ranks better than 87.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lagis Enterprise Co's EBITDA for the
three
months ended in Dec. 2025 was NT$35.4 Mil. Lagis Enterprise Co's Revenue for the
three
months ended in Dec. 2025 was NT$123.9 Mil. Therefore, Lagis Enterprise Co's EBITDA margin for the quarter that ended in Dec. 2025 was 28.57%.
Lagis Enterprise Co (ROCO:6730) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lagis Enterprise Co EBITDA Margin % Related Terms
Lagis Enterprise Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lagis Enterprise Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6730 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Lagis Enterprise Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lagis Enterprise Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lagis Enterprise Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lagis Enterprise Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lagis Enterprise Co (ROCO:6730) has a EBITDA Margin % of 28.57% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lagis Enterprise Co and its competitors. This is near median its historical median of 27.19. Over the past decade, Lagis Enterprise Co's EBITDA Margin % has ranged from 21.24 to 34.52. According to the industry distribution chart, Lagis Enterprise Co ranks #104 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 12.7%.
Is Lagis Enterprise Co's EBITDA Margin % too high?
Lagis Enterprise Co's current EBITDA Margin % of 28.57% is near median its 10-year median of 27.19. Over the past 10 years, this metric has ranged from a low of 21.24 to a high of 34.52. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Lagis Enterprise Co's value of 28.57% is 282.2% above this industry median. Based on the distribution chart, Lagis Enterprise Co ranks #104 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lagis Enterprise Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lagis Enterprise Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Lagis Enterprise Co ranks #104 out of 816 companies for EBITDA Margin %. This places Lagis Enterprise Co in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Lagis Enterprise Co's value of 28.57% is 282.2% above this benchmark. Historically, Lagis Enterprise Co's own EBITDA Margin % has ranged from 21.24 to 34.52 over the past decade. While the company's 10-year median is 27.19 vs. the industry median of 7.48, Lagis Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lagis Enterprise Co's current EBITDA Margin % of 28.57% is 282.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lagis Enterprise Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lagis Enterprise Co's current EBITDA Margin % is 28.57%, which is near median its own 10-year median of 27.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lagis Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Lagis Enterprise Co (ROCO:6730) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.10, compared to a current price of NT$37.50 — trading 13% below its estimated fair value. The current EBITDA Margin % is 28.57%, which is near median its 10-year median of 27.19 and 282.2% above the Medical Devices & Instruments industry median of 7.48. Lagis Enterprise Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lagis Enterprise Co (ROCO:6730), the current EBITDA Margin % is 28.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lagis Enterprise Co (ROCO:6730) Overvalued in 2026?
Based on GuruFocus' analysis, Lagis Enterprise Co stock appears to be undervalued.
The current stock price of NT$37.50 is trading 13% below its estimated GF Value™ of NT$43.10.
GuruFocus considers Lagis Enterprise Co to be Modestly Undervalued.
Key valuation signals for ROCO:6730:
EBITDA Margin %: 28.57% (near median its 10-year median of 27.19)
GF Value™: NT$43.10 vs. price of NT$37.50 (13% below fair value)
Industry Position: 282.2% above the Medical Devices & Instruments median (#104 of 816)
No single metric tells the full story. See the ROCO:6730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lagis Enterprise Co Ltd is a medical device development company that designs, patents, and markets medical devices for the laparoscopic and endoscopic surgical markets. Its product portfolio includes Access, Endo Devices, Specimen Retrieval products, Suction Irrigation systems, Training systems, and accessories.
91GF Score
Get the complete analysis for ROCO:6730
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6730 has been successfully added to your 
